Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 14
Submit an article Journal homepage
165
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab

Robert Stuvera Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0991-5170View further author information
ORCID Icon,
Santosha A. Vardhanaa Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Akshay Bedmuthab Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-5683-4918View further author information
ORCID Icon,
Karmela Kim Chanc Hospital for Special Surgery, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-8619-8588View further author information
ORCID Icon,
Rosna Mirtcheva-Trochevab Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Anton Nosovb Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Heiko Schöderb Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
&
Alison Moskowitza Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
 show all
Pages 2351-2353 | Received 27 Aug 2023, Accepted 19 Sep 2023, Published online: 05 Oct 2023

References

  • Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132. doi:10.1200/JCO.2016.72.1316
  • Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294. doi:10.1016/S1470-2045(16)30167-X
  • Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(17 Suppl.):LBA4. doi:10.1200/JCO.2023.41.17_suppl.LBA4
  • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
  • Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694
  • Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. doi:10.1200/JCO.21.01440
  • Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–2878. doi:10.1200/JCO.2018.79.0006
  • Maslov DV, Tawagi K, Kc M, et al. Original research: timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer. 2021;9(7):e002261. doi:10.1136/jitc-2020-002261
  • Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213. doi:10.1136/esmoopen-2017-000213
  • Ricciuti B, Dahlberg SE, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019;37(22):1927–1934. doi:10.1200/JCO.19.00189
  • Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198. doi:10.1200/JCO.2015.60.8448
  • Riudavets M, Mosquera J, Garcia-Campelo R, et al. Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents. Front Oncol. 2020;10:1677. doi:10.3389/fonc.2020.01677
  • Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(4):387–405. doi:10.6004/jnccn.2022.0020
  • Belkhir R, Le Burel S, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747–1750. doi:10.1136/annrheumdis-2017-211216
  • Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48(3):553–557. doi:10.1016/j.semarthrit.2018.02.011
  • Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and ­relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393–398. doi:10.1136/annrheumdis-2017-212257
  • Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–154. doi:10.1038/s41584-020-0373-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.